StockNews.AI
LLY
StockNews.AI
193 days

Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years

1. Eli Lilly's Omvoh shows over 90% sustained remission in Crohn's disease patients after two years. 2. Data emphasizes Omvoh's long-term efficacy and safety for Crohn's and ulcerative colitis.

3m saved
Insight
Article

FAQ

Why Bullish?

These results support LLY's product pipeline, showcasing strong demand and efficacy.

How important is it?

Positive trial results for Omvoh can significantly affect LLY's growth trajectory and investor sentiment.

Why Long Term?

Sustained efficacy data can influence physician prescribing patterns, bolstering LLY's market position.

Related Companies

ABBVJNJ
More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of patients who achieved endoscopic response at one year sustained it at two years Omvoh is the first IL-23p19 antagonist to demonstrate multi-year, sustained efficacy and safety for both Crohn's disease and ulcerative colitis INDIANAPOLIS , Feb. 7, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two years of continuous treatment with Omvoh® (mirikizumab-mrkz) achieved long-term clinical and endoscopic outcomes, including those (43.8%) with previous biologic failure. Data from this study will be presented at the Crohn's and Colitis Congress (CCC), being held from February 6-8, 2025 in San Francisco.1 Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation.2,3 "Many people living with Crohn's disease have tried available therapies without success or have experienced a loss of efficacy with their treatment," said Edward Barnes, M.D.

Related News